Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

CONCLUSIONS: This case and the review of current data confirm the benefit of BRAF inhibition in BRAF-mutated ATC, limited by acquired resistance to targeted therapy.PMID:36855200 | DOI:10.1186/s13044-023-00147-7

Source: Cell Research - March 1, 2023 Category: Cytology Authors: Matthias Lang Thomas Longerich Chrysanthi Anamaterou Source Type: research